ArticleMolecular medicine reports2018
Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- TCF12-mediated transcriptional activation of CCDC34 is involved in the positive feedback of tumor-associated macrophages and EMT to promote LUSC.Cell biology and toxicology · 2026Article
- The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential.Journal of neuro-oncology · 2025Article
- CCDC34 maintains stemness phenotype through β-catenin-mediated autophagy and promotes EGFR-TKI resistance in lung adenocarcinoma.Cancer gene therapy · 2025Article
- Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents.Cell communication and signaling : CCS · 2024Review
- Comprehensive pan-cancer analysis reveals CCDC58 as a carcinogenic factor related to immune infiltration.Apoptosis : an international journal on programmed cell death · 2024Article
- A machine learning model identifies M3-like subtype in AML based on PML/RARα targets.iScience · 2024Article
- Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk.Human genomics · 2024Article
- MNX1 facilitates the malignant progress of lung adenocarcinoma through transcriptionally upregulating CCDC34.Oncology letters · 2023Article
- Comprehensive analysis reveals CCDC60 as a potential biomarker correlated with prognosis and immune infiltration of head and neck squamous cell carcinoma.Frontiers in oncology · 2023Article
- Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol.Pharmacogenomics and personalized medicine · 2022Article
- CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer.Aging · 2021Article
- CCDC137 Is a Prognostic Biomarker and Correlates With Immunosuppressive Tumor Microenvironment Based on Pan-Cancer Analysis.Frontiers in molecular biosciences · 2021Article
- Article
- High expression of eukaryotic initiation factor 3M predicts poor prognosis in colon adenocarcinoma patients.Oncology letters · 2020Article
- Colorectal Cancer Immunotherapy: Options and Strategies.Frontiers in immunology · 2020Review
- Roles of eIF3m in the tumorigenesis of triple negative breast cancer.Cancer cell international · 2020Article
- Up-Regulated CCDC34 Contributes to the Proliferation and Metastasis of Hepatocellular Carcinoma.OncoTargets and therapy · 2020Article
- Decreased expression of EFCC1 and its prognostic value in lung adenocarcinoma.Annals of translational medicine · 2019Article
- High Expression of CCDC34 Is Associated with Poor Survival in Cervical Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been previously reported that increased expression of coiled‑coil domain containing 34 (CCDC34), a member of the CCDCs family, may promote the proliferation and invasion of bladder cancer cells. However, its role in colorectal cancer (CRC) remains unclear. The present study investigated CCDC34 expression in CRC tissues and determined the association between CCDC34 expression and biological characteristics in patients with CRC. Additionally, the variation of cell activity, apoptosis, invasion and associated mechanisms were evaluated following CCDC34 inhibition in SW620 cells with small interfering RNA (siRNA). The role of CCDC34 in CRC growth, apoptosis and invasion was investigated. In the current study, immunohistochemistry revealed an overexpression of CCDC34 in CRC tissues compared with paracancerous tissue (χ2=29.810; P<0.001). Furthermore, CCDC34 expression was revealed to be associated with tumor invasion depth and lymphatic metastasis (χ2=4.343, P=0.037; χ2=7.915, P=0.005). Additionally, the inhibition of CCDC34 expression in SW620 cells led to reduced tumor cell activity, increased apoptosis rate and reduced invasion ability, and expression of apoptosis and invasion‑associated genes varied simultaneously which demonstrated that B cell leukemia/lymphoma 2, survivin, N‑cadherin, and MMP‑9 were decreased, whereas E‑cadherin increased significantly in cells of CCDC34‑siRNA group compared with the control group (P<0.05). Therefore, CCDC34 may contribute to CRC development by inhibiting apoptosis of cancer cells and promoting invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.